Premenstrual Dysphoric Disorder.

Teri Pearlstein, Teresa Lanza di Scalea

Journal: The Psychiatric clinics of North America 2018;40(2):201-216

PMID: 28477648

Full Text on Elsevier Science View on PubMed

Abstract

Premenstrual dysphoric disorder (PMDD) comprises emotional and physical symptoms and functional impairment that lie on the severe end of the continuum of premenstrual symptoms. Women with PMDD have a differential response to normal hormonal fluctuations. This susceptibility may involve the serotonin system, altered sensitivity of the GABA receptor to the neurosteroid allopregnanalone, and altered brain circuitry involving emotional and cognitive functions. Serotonin reuptake inhibitors are considered the first-line treatment. Second-line treatments include oral contraceptives containing drospirenone, other ovulation suppression methods, calcium, chasteberry, and cognitive-behavioral therapy.

Address: Department of Psychiatry, Rhode Island Hospital and Miriam Hospital, 593 Eddy Street, Providence, RI 02903, USA. Electronic address: [email protected].; Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Women's Behavioral Medicine, Women's Medicine Collaborative, Miriam Hospital, 146 West River Street, Providence, RI 02904, USA.

DOI: 10.1016/j.psc.2017.01.002

Link outs

Free resources

Medical:

https://medlineplus.gov/premenstrualsyndrome.html

Other Literature Sources:

https://scite.ai/reports/28477648

Subscription / membership required

Full Text Sources:

MeSH Terms: Contraceptives, Oral, Female, Humans, Premenstrual Dysphoric Disorder, Premenstrual Syndrome, Selective Serotonin Reuptake Inhibitors